 |
7 Diseases |  |
10 Trials |
|
10 Trials |  |
866 News |  |
| «123456789 |
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes (clinicaltrials.gov) - Jan 12, 2014
P1, N=39, Recruiting, Sponsor: Novo Nordisk
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 8, 2014
P1, N=46, Recruiting, Sponsor: Novo Nordisk
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Dec 9, 2013
P1, N=36, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes (clinicaltrials.gov) - Dec 4, 2013
P1, N=44, Completed, Sponsor: Novo Nordisk A/S
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P3 trial: onset (clinicaltrials.gov) - Dec 1, 2013
P3, N=36, Active, not recruiting, Sponsor: Novo Nordisk A/S
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Nov 21, 2013
P1, N=48, Completed, Sponsor: Novo Nordisk
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes (clinicaltrials.gov) - Sep 2, 2013
P1, N=43, Completed, Sponsor: Novo Nordisk
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Aug 14, 2013
P1, N=36, Completed, Sponsor: Novo Nordisk
- || Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P3 trial, Combination therapy: Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 7, 2013
P3, N=286, Active, not recruiting, Sponsor: Novo Nordisk A/S
- || Levemir (insulin detemir rDNA origin) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P3 trial, Combination therapy: Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes (clinicaltrials.gov) - Apr 11, 2013
P3, N=1095, Active, not recruiting, Sponsor: Novo Nordisk A/S
- || Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P3 trial, Combination therapy: onset 2: Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes (clinicaltrials.gov) - Mar 25, 2013
P3, N=676, Active, not recruiting, Sponsor: Novo Nordisk A/S
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
Trial completion: A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog (clinicaltrials.gov) - Mar 14, 2013
P1, N=43, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Sep 11, 2012
P1, N=52, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
New P1 trial: A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog (clinicaltrials.gov) - Sep 9, 2012
P1, N=43, Completed, Sponsor: Novo Nordisk
- ||| Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jun 11, 2012
P1, N=52, Completed, Sponsor: Novo Nordisk
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
Trial completion: A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Jan 12, 2012
P1, N=40, Completed, Sponsor: Novo Nordisk
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Trial Investigating the Pharmacokinetic Properties of Formulations of NN1218 in Subjects With Type 1 Diabetes (clinicaltrials.gov) - Nov 7, 2011
P1, N=40, Completed, Sponsor: Novo Nordisk